GDC-9545

Giredestrant (GDC-9545 and RG6171) is a SERD. GDC-9545 is an orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Giredestrant has anti-tumor activity.


Cat. No.: EX-A3541	Purity: >98%

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
25mg	550	In-stock
50mg	750	In-stock
100mg	980	In-stock
200mg	1450	In-stock
1g	3500	In-stock
5g	9500	In-stock

Send PO to E-mail:order@excenen.com; or Fax:+86 020 81619670

Discount Request


Synonyms	Giredestrant
Synonyms 2	RG 6171
CAS No.	1953133-47-5
Purity	>98%
Formula	C27H31F5N4O
Mol Weight	522.5533
Appearance	Yellow Solid
Solubility	Soluble in DMSO, not in water
Shelf Life	>2 years if stored properly
Storage	Powder -20℃ 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Liang J, Zbieg JR, Blake RA, et al. GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer. J Med Chem. 2021;64(16):11841-11856. doi:10.1021/acs.jmedchem.1c00847 [2]. Liang J, Ingalla ER, Yao X, et al. Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer. Sci Transl Med. 2022;14(663):eabo5959. doi:10.1126/scitranslmed.abo5959 [3]. Chen YC, Yu J, Metcalfe C, et al. Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer. Expert Opin Investig Drugs. 2022;31(6):515-529. doi:10.1080/13543784.2021.1983542 [4]. C Metcalfe, et al. Abstract P5-04-07: GDC-9545: A novel ER antagonist and clinical candidate that combines desirable mechanistic and pre-clinical DMPK attributes
CoA	CoA of GDC-9545

Smiles:	OCC(F)(F)CN([C@@H]1C2=C(F)C=C(NC3CN(CCCF)C3)C=C2F)[C@H](C)CC4=C1NC5=C4C=CC=C5


		Search